X4 Pharmaceuticals (XFOR) Short term Debt (2017 - 2023)

X4 Pharmaceuticals' Short term Debt history runs 6 years deep, the most recent figure standing at $764000.0 for Q2 2023.

• Quarterly Short term Debt fell 91.12% year-over-year to $764000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $764000.0 (down 91.12% YoY) and the FY2022 annual result came in at $1.3 million, up 65.41% from the prior year.
• Short term Debt was $764000.0 for Q2 2023 at X4 Pharmaceuticals, up from $554000.0 in the prior quarter.
• Across five years, Short term Debt topped out at $14.6 million in Q3 2022 and bottomed at $554000.0 in Q1 2023.
• A 4-year average of $4.0 million and a median of $2.4 million in 2022 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2022 — Short term Debt jumped 2009.81% — and 2023, when it sank 91.12%.
• X4 Pharmaceuticals' Short term Debt stood at $4.2 million in 2019, then plunged by 80.85% to $795000.0 in 2021, then surged by 65.41% to $1.3 million in 2022, then sank by 41.9% to $764000.0 in 2023.
• Business Quant data shows XFOR's Short term Debt at $764000.0 in Q2 2023, $554000.0 in Q1 2023, and $1.3 million in Q4 2022.